Register
|
Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC
Specialties >>
AML
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancers
HCC
Head & Neck Cancers
Hematology
HER2-Negative Breast Cancer
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Sarcoma
Skin Cancers
Thyroid Cancers
Partners >>
Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up
The Journal of Targeted Therapies in Cancer
2017 February
Clinical Articles
Missing Tumor-Specific Mutations Lead to Increased Resistance to Checkpoint Inhibitors
Axicabtagene Ciloleucel Demonstrates Safety and Efficacy in Lymphoma
Clinical Development of Cyclin-Dependent Kinase Inhibitors in Lung Cancer
Immune Checkpoint Inhibitors in CRC
Immune Checkpoint Approaches in AML and MDS: A Next Frontier?
JTT Articles
The Role of Liquid Biopsy in NSCLC Continues to Emerge
Rare Incidence of ICI-Related Hepatotoxicity Frequently Ends in Treatment Discontinuation
Researchers Look to CAR T-Cell Therapy as Immunotherapy Outcomes Diminish in Glioblastoma
>> View Peer-Reviewed Articles
Most Popular
Key Takeaway Points in Phase III ALCYONE Trial for Multiple Myeloma
Finasteride Effective in Preventing Prostate Cancer
Enzalutamide Leads to Extended Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
Lenalidomide Maintenance Improves PFS, OS in Patients With Transplant-Eligible Multiple Myeloma